Contact us

Investor Information

Stéphane Bette - Director, Co-Founder and Chief Executive Officer

Stéphane Bette,
Co founder and Deputy CEO

Pierre Jérôme - Co-Founder

Pierre Jérôme,
Co founder, CEO & Chairman

Dear Shareholders,

The webinar organized in April 2021 was an opportunity to review our 2021 results, to underline our latest progress and to share with you our perspectives on SpineGuard your company that we founded with the ambition, still intact, to make spine surgery safer and to exploit the full potential of DSG® (Dynamic Surgical Guidance) technology, unique in its ability to differentiate bony tissues in real-time and without using X-Rays.

Read the latest Financial News

Stock Information

Stock exchange information

  • ISIN code: FR0011464452
  • Stock Quote: ALSGD
  • Number of shares: 29.734.572
  • Sector: Medical technologies
  • Principal Index: Alternext All-share
  • Exchange: Euronext-Growth
  • Place of listing: Euronext Paris (France)
  • Eligibility to French PEA/SRD: Yes/No
  • Eligibility French PEA-PME: Yes

Financial agenda

  • 26 January 2022: 2021 Full-Year Sales
  • 27 January 2022: Investor Webinar
  • 20 April 2022: 2021 Full-Year Results
  • 20 April 2022: 2022 First-Quarter Sales
  • 8 June 2022: Annual Shareholders Meeting
  • 12 July 2022: 2022 First-Half Sales
  • 14 September 2022: 2022 First-Half Results
  • 12 October 2022: 2022 Third-Quarter Sales


  • Biostrategic Research: Lionel Labourdette


  • Liquidity contract: Tradition Securities And Futures (TSAF)
  • Auditors: Grant Thornton
  • Listing Sponsor: Swiss Life Banque Privée

Shareholders structure

(August 31th, 2021)

Stock quotes

  • To check the stock quote in real time, click here

For any request, don't hesitate to contact us